Zeidner, J. F., Sallman, D. A., Récher, C., Daver, N. G., Leung, A. Y. H., Hiwase, D. K., Subklewe, M., Pabst, T., Montesinos, P., Larson, R. A., Wilde, L., Enjeti, A. K., Kawashima, I., Papayannidis, C., O’Nions, J., Johnson, L., Dong, M., Huang, J., Bagheri, T., Kleiman, G. H., Lee, C., Vyas, P. (2025). Magrolimab plus azacitidine vs physician’s choice for untreated <i>TP53</i>-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. https://doi.org/10.1182/blood.2024027408